Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.
暂无分享,去创建一个
B. Coiffier | H. Tilly | C. Gisselbrecht | É. Lepage | C. Haioun | P. Morel | R. Herbrecht | M. d'Agay | A. Bosly | C. Nouvel | M. D'agay
[1] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[2] M. Strawderman,et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] D. Neuberg,et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Montserrat,et al. Autologous bone marrow transplantation for non-Hodgkin's lymphoma in first remission. , 1993, Blood.
[5] B. Coiffier,et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Coiffier,et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. , 1992, Blood.
[7] A. Nademanee,et al. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. , 1992, Blood.
[8] C. Le Forestier,et al. A simple, efficient washing procedure for cryopreserved human hematopoietic stem cells prior to reinfusion. , 1991, Bone marrow transplantation.
[9] J. Armitage,et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] B. Yeap,et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] B. Coiffier,et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Armitage. Bone marrow transplantation in the treatment of patients with lymphoma. , 1989, Blood.
[13] I. Henderson,et al. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Armitage,et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] B. Shank,et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] U. Vitolo,et al. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity. , 1988, Haematologica.
[17] J. Armitage,et al. The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. , 1988, Seminars in hematology.
[18] F. Berger,et al. Intensive chemotherapy in aggressive lymphomas: updated results of LNH-80 protocol and prognostic factors affecting response and survival. , 1987, Blood.
[19] J. Armitage,et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.
[20] J. Connors,et al. Updated clinical experience with MACOP-B. , 1987, Seminars in hematology.
[21] B. Clarkson,et al. Predictive model for prognosis in advanced diffuse histiocytic lymphoma. , 1986, Cancer research.
[22] G. Pinkus,et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. , 1986, Annals of internal medicine.
[23] D. Cox,et al. Analysis of Survival Data. , 1985 .
[24] H Stein,et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[25] R. Fisher,et al. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. , 1977, The American journal of medicine.
[26] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[27] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[28] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[29] E. Jaffe,et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.